SPOTLIGHT -
FDA Grants Priority Review to Liso-Cel in Relapsed/Refractory CLL/SLL
The FDA acceptance marks the first step in addressing the unmet need for a lasting treatment option for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
